US4523271090
© PR Newswire
11.12.2025
ILMN
LISTED
NASDAQ
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
News Preview
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO and MENLO PARK, Calif., Dec. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today ann...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2025
ILMN
LISTED
NASDAQ
Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study
News Preview
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood pressure and cholesterol
Results demonstrate the...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ILMN
LISTED
NASDAQ
Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks
News Preview
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed
Sydney Mass Spectrometry is the first facility...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
05.11.2025
ILMN
LISTED
NASDAQ
Illumina Responds to Positive Updates from Chinese Ministry of Commerce
News Preview
SAN DIEGO, Nov. 5, 2025 /PRNewswire/ -- The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban on Illumina, Inc. (NASDAQ: ILMN), which had been in place since March 4, 2025. While the ban will be lifted on November 10, Illumina remains on the Unreliable Entities List (UEL), requirin...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
30.10.2025
ILMN
LISTED
NASDAQ
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025
News Preview
Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis
GAAP operating margin of 21.0% and non-GAAP operating margin of 24.5% for Q3 2025
GAAP diluted EPS of $0.98 and non-GAAP diluted EPS of $1.34 for Q3 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ILMN
LISTED
NASDAQ
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
News Preview
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx
Constellation outperformed orthogonal methods in identifying select difficult-to-map variants
SAN DIEGO, Oct. 17, 2...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ILMN
LISTED
NASDAQ
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
News Preview
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx
Constellation outperformed orthogonal methods in identifying select difficult-to-map variants
SAN DIEGO, Oct. 17, 2...
Themefolio
Profiler
Peergroup
© PR Newswire
16.10.2025
ILMN
LISTED
NASDAQ
Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights
News Preview
At ASHG, an early access customer from the London Health Sciences Center Research Institute demonstrated the power of the 5-base genome for accelerating resolution of rare disease cases
Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic i...
Themefolio
Profiler
Peergroup
© PR Newswire
16.10.2025
ILMN
LISTED
NASDAQ
Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights
News Preview
At ASHG, an early access customer from the London Health Sciences Center Research Institute demonstrated the power of the 5-base genome for accelerating resolution of rare disease cases
Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic i...
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2025
ILMN
LISTED
NASDAQ
Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights
News Preview
At ASHG, an early access customer from the London Health Sciences Center Research Institute will demonstrate the power of the 5-base genome for accelerating resolution of rare disease cases
Proprietary 5-base chemistry and novel DRAGEN algorithms enable du...
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2025
ILMN
LISTED
NASDAQ
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
News Preview
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx
Constellation outperformed orthogonal methods in identifying select difficult-to-map variants
SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare d...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ILMN
LISTED
NASDAQ
Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025
News Preview
SAN DIEGO, Oct. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2025 following the close of market on Thursday, October 30, 2025.
On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Execu...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
01.10.2025
ILMN
LISTED
NASDAQ
Illumina launches new business to accelerate technology and data-driven discovery
News Preview
New business focuses on developing data assets, software, and AI to
fuel life science breakthroughs
Expands pharma access to large omics datasets to
advance target discovery and drug development...
Themefolio
Profiler
Peergroup
© PR Newswire
23.09.2025
ILMN
LISTED
NASDAQ
Illumina advances personalized cancer care with new pharma development partnerships
News Preview
Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker
SAN DIEGO, Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight™ Oncology (TSO) Comprehensive genomic profili...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ILMN
LISTED
NASDAQ
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
News Preview
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines
Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people
SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN),...
Themefolio
Profiler
Peergroup
© PR Newswire
07.09.2025
ILMN
LISTED
NASDAQ
Illumina® Protein Prep bringt neue Erkenntnisse aus der Proteomik für eine verbesserte Arzneimittelforschung und -entwicklung
News Preview
Illumina Protein Prep kann 9500 einzigartige menschliche Protein-Targets messen und bietet damit neue Einblicke in die Proteinbiologie, um die Entdeckung neuer Behandlungsmöglichkeiten für Krankheiten zu fördern
Nach dem Early-Access-Programm loben die Kunden die Skalierbarkeit, die hohe Konsistenz und den einfachen Einblick in den Workflow.
Die...
Themefolio
Profiler
Peergroup
© PR Newswire
03.09.2025
ILMN
LISTED
NASDAQ
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
News Preview
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease
Following early access program, customers commend scale, high consistency, and easy sample to insights workflow
Launch follows Illumina's announcement of agreement to acquire SomaLogic
S...
Themefolio
Profiler
Peergroup
© PR Newswire
03.09.2025
ILMN
LISTED
NASDAQ
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
News Preview
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease
Following early access program, customers commend scale, high consistency, and easy sample to insights workflow
Launch follows Illumina's announcement of agreement to acquire SomaLogic
S...
Themefolio
Profiler
Peergroup
© PR Newswire
03.09.2025
ILMN
LISTED
NASDAQ
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
News Preview
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease
Following early access program, customers commend scale, high consistency, and easy sample to insights workflow
Launch follows Illumina's announcement of agreement to acquire SomaLog...
Themefolio
Profiler
Peergroup
© PR Newswire
03.09.2025
ILMN
LISTED
NASDAQ
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
News Preview
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease
Following early access program, customers commend scale, high consistency, and easy sample to insights workflow
Launch follows Illumina's announcement of agreement to acquire SomaLog...
Themefolio
Profiler
Peergroup
© PR Newswire
19.08.2025
ILMN
LISTED
NASDAQ
Nilesh Shah joins Illumina as Head of Region, AMEA
News Preview
SINGAPORE, Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of Nilesh Shah as Head of Region, AMEA, effective immediately.
Nilesh brings over 25 years of leadership experience in the medical technology and life sciences industries, having h...
Themefolio
Profiler
Peergroup
© PR Newswire
19.08.2025
ILMN
LISTED
NASDAQ
Nilesh Shah joins Illumina as Head of Region, AMEA
News Preview
SINGAPORE, Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of Nilesh Shah as Head of Region, AMEA, effective immediately.
N...
Themefolio
Profiler
Peergroup
© PR Newswire
31.07.2025
ILMN
LISTED
NASDAQ
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025
News Preview
Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basisGAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19 for Q2 2025Cash provided by operations of $234 million and free cash flow of $204 million for Q2 2025F...
Themefolio
Profiler
Peergroup
© PR Newswire
30.07.2025
ILMN
LISTED
NASDAQ
Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling
News Preview
Illumina TruSight™ Oncology 500 v2 research assay is now available with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input
Illumina's growing research and clinical oncology portfolio broadens access to critical biomarker testing
SAN DIEGO, July 30, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today a...
Themefolio
Profiler
Peergroup
© PR Newswire
10.07.2025
ILMN
LISTED
NASDAQ
Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025
News Preview
SAN DIEGO, July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025.
On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Off...
Themefolio
Profiler
Peergroup
© PR Newswire
10.07.2025
ILMN
LISTED
NASDAQ
Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year
News Preview
Illumina was also recognized as one of the Best Companies to Work For byU.S. News & World Report
SAN DIEGO, July 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced two awards recognizing the company's leadership in sustainability practices and as an employer of choice. TIME named Illumina to its World's Most Sustainable Com...
Themefolio
Profiler
Peergroup
© PR Newswire
25.06.2025
ILMN
LISTED
NASDAQ
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
News Preview
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach
Positions Illumina to achieve growth in a large, expanding market
Illumina and SomaLogic have partnered in proteomics co-development since late 2021
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) a...
Themefolio
Profiler
Peergroup
© PR Newswire
25.06.2025
ILMN
LISTED
NASDAQ
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
News Preview
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach
Positions Illumina to achieve growth in a large, expanding market
Illumina and SomaLogic have partnered in proteomics co-development since late 2021
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) a...
Themefolio
Profiler
Peergroup
© PR Newswire
23.06.2025
ILMN
LISTED
NASDAQ
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
News Preview
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach
Positions Illumina to achieve growth in a large, expanding market
Illumina and SomaLogic have partnered in proteomics co-development since late 2021
SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) a...
Themefolio
Profiler
Peergroup
© PR Newswire
10.06.2025
ILMN
LISTED
NASDAQ
lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics
News Preview
SAN DIEGO, June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) Report. The report spotlights the ways Illumina is making precision health more accessible than ever before, and its ongoing work to empower people...
Themefolio
Profiler
Peergroup
© PR Newswire
29.05.2025
ILMN
LISTED
NASDAQ
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
News Preview
New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time
SAN DIEGO, May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncodin...
Themefolio
Profiler
Peergroup
© PR Newswire
28.05.2025
ILMN
LISTED
NASDAQ
Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
News Preview
Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies
Illumina's IVD portfolio will also expand to offer Pillar oncoReveal® CDx, the newest panel to deliver critical companion diagnostic testing using the...
Themefolio
Profiler
Peergroup
© PR Newswire
14.05.2025
ILMN
LISTED
NASDAQ
Illumina To Webcast Upcoming Investor Conference
News Preview
SAN DIEGO, May 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:
41st Annual Bernstein Strategic Decisions Conference on May 28, 2025Fireside chat at 11:30am Pacific Time (2:30pm Eastern Time)The webcast can be accessed through the Investor Info secti...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2025
ILMN
LISTED
NASDAQ
Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications
News Preview
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling
New features include easy-to-use oncology apps, enhanced multiomics pipelines, and AWS F2 support enabling faster turnaround times
SAN DIEGO, May 13, 2025 /PRNewswire/ -- Illumina Inc. (NASDA...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2025
ILMN
LISTED
NASDAQ
Illumina Reports Financial Results for First Quarter of Fiscal Year 2025
News Preview
Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis)GAAP operating margin of 15.8% and non-GAAP operating margin of 20.4% for Q1 2025GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $0.97 for Q1 2025Cash provided by operations of $240 million and free cash flow of $208 million for Q1 20...
Themefolio
Profiler
Peergroup
© PR Newswire
01.05.2025
ILMN
LISTED
NASDAQ
Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
News Preview
First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies
Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies
SAN DIEGO, May 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ...
Themefolio
Profiler
Peergroup
© PR Newswire
15.04.2025
ILMN
LISTED
NASDAQ
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
News Preview
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease
SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announc...
Themefolio
Profiler
Peergroup
© PR Newswire
10.04.2025
ILMN
LISTED
NASDAQ
Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025
News Preview
SAN DIEGO, April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025.
On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Offic...
Themefolio
Profiler
Peergroup
© PR Newswire
25.03.2025
ILMN
LISTED
NASDAQ
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
News Preview
Stephen MacMillan to retire from the Board
SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of...
Themefolio
Profiler
Peergroup
© PR Newswire
19.03.2025
ILMN
LISTED
NASDAQ
Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery
News Preview
Creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program
AGD members are using the population-level insights to uncover novel drug targets
SAN DIEGO, March 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a le...
Themefolio
Profiler
Peergroup
© PR Newswire
10.03.2025
ILMN
LISTED
NASDAQ
Illumina addresses recent developments in China
News Preview
Announces Fiscal Year 2025 Non-GAAP Diluted EPS of Approximately $4.50
SAN DIEGO, March 10, 2025 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the March 4, 2025 notice from the China Ministry of Commerce ("MOFCOM") that Illumina is not permitted to export sequencing instruments into China. Illumina...
Themefolio
Profiler
Peergroup
© PR Newswire
06.03.2025
ILMN
LISTED
NASDAQ
Illumina named to Dow Jones Best-in-Class Indices for sixth consecutive year and as a Sustainability Yearbook Member for fourth consecutive year
News Preview
Illumina leads as highest-scoring U.S. company in its industry
SAN DIEGO, March 6, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, has been named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow Jones Best-in-Class North America Index (formerl...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
ILMN
LISTED
NASDAQ
Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions
News Preview
Longstanding partners bring together end-to-end workflows and leading CRISPRPerturb-seq technologies setting a standard for single-cell studies and enabling a 5billion single-cell atlas ecosystem within three years
SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-ba...
Themefolio
Profiler
Peergroup
© PR Newswire
18.02.2025
ILMN
LISTED
NASDAQ
Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference
News Preview
SAN DIEGO, Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session at the AGBT conference.
The investor fireside chat will begin at 8:00am Pacific Time (11:00am Eastern Time) on Tuesday, February 25, 2025 and wil...
Themefolio
Profiler
Peergroup
© PR Newswire
06.02.2025
ILMN
LISTED
NASDAQ
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2024
News Preview
Core Illumina revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4.3 billion for fiscal year 2024, down 2% from fiscal year 2023 on both a reported and constant currency basisCore Illumina GAAP operating margin of 15.8% and non-GAAP operating margin of 19.7% for Q4 2024; GAAP operat...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2025
ILMN
LISTED
NASDAQ
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025
News Preview
SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2024 and preliminary outlook for fiscal year 2025 ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 at...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
ILMN
LISTED
NASDAQ
Illumina and NVIDIA collaborate to decode biology and propel precision health
News Preview
Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models
SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platfo...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2025
ILMN
LISTED
NASDAQ
Illumina advances NovaSeq X Series, delivering single-flow-cell system, software upgrade, and new kits to enable multiomic applications
News Preview
Software upgrade advances complete workflow solutions
New NovaSeq X 25B 100-cycle and 200-cycle kits enhance multiomic capabilities on NovaSeq X, and enable newly released Illumina Single-Cell Prep
SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today annou...
Themefolio
Profiler
Peergroup
© PR Newswire
23.12.2024
ILMN
LISTED
NASDAQ
Macrogen Consortium win tender for National Bio Big Data Project
News Preview
Illumina is proud to be selected as sequencing technology partner to the Macrogen Consortium.
SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Macrogen a global healthcare company that specializes in precision medicine and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today that they are...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2024
ILMN
LISTED
NASDAQ
Illumina To Webcast Upcoming Investor Conference
News Preview
SAN DIEGO, Dec. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:
43rd Annual J.P. Morgan Healthcare Conference on January 14, 2024Presentation at 9:00am Pacific Time (12:00pm Eastern Time) immediately followed by a Q&A Session to begin at approxim...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2024
ILMN
LISTED
NASDAQ
Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications
News Preview
Agreement grants access to Synaffix patent portfolio related to metal-free click chemistryTechnology to be used in Illumina's next-generation sequencing (NGS) products AMSTERDAM, Dec. 4, 2024 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage bioconjugation platform technology for the developme...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2024
ILMN
LISTED
NASDAQ
Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications
News Preview
Agreement grants access to Synaffix patent portfolio related to metal-free click chemistryTechnology to be used in Illumina's next-generation sequencing (NGS) products AMSTERDAM, Dec. 4, 2024 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage bioconjugation platform technology for the developme...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2024
ILMN
LISTED
NASDAQ
Illumina announces expansion of TruSight Oncology portfolio
News Preview
The latest solution to enable comprehensive genomic profiling of tumors will be presented at the annual meeting of the Association of Molecular Pathology
Customer-led research and presentations at the conference will deliver the latest evidence and education in tumor profiling
SAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: I...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
ILMN
LISTED
NASDAQ
Illumina To Webcast Upcoming Investor Conferences
News Preview
SAN DIEGO, Nov. 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences:
Wolfe Research 2024 Healthcare Conference on November 20, 2024Firesid...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
ILMN
LISTED
NASDAQ
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2024
News Preview
Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basisCore Illumina GAAP operating margin of 68.6% and non-GAAP operating margin of 22.6% for Q3 2024Core Illumina GAAP diluted EPS of $4.03 and non-GAAP diluted EPS of $1.14 for Q3 2024Lowered fiscal year 2024 Core Illumina revenue guidance to decli...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
ILMN
LISTED
NASDAQ
Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting
News Preview
New, groundbreaking technology delivers Illumina's most comprehensive genome yet; early results from Broad Clinical Labs demonstrate a highly simplified workflow, ultra-long phasing, high-resolution insights into complex genomic variation, and enhanced long-range information Illumina and customers will also showcase new details on complete prote...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2024
ILMN
LISTED
NASDAQ
Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers
News Preview
Designed to make next-generation sequencing accessible to more labs
With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries
SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today unvei...
Themefolio
Profiler
Peergroup
© PR Newswire
09.10.2024
ILMN
LISTED
NASDAQ
Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers
News Preview
Designed to make next-generation sequencing accessible to more labs
With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries
SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today un...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
ILMN
LISTED
NASDAQ
Illumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024
News Preview
SAN DIEGO, Oct. 7, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2024 following the close of market on Monday, November 4, 2024.
On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Off...
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2024
ILMN
LISTED
NASDAQ
Charles Dadswell to step down as General Counsel, Illumina initiates search for successor
News Preview
SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that after 11 years of service, Charles "Chuck" Dadswell will step down as General Counsel and Secretary on October 3. Dadswell has agreed to remain an Illumina employee, serving as an advisor to CEO Jac...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
